We develop new pharmaceutical products for the treatment of genitourinary tumors and related diseases

News Releases

Asieris Pharmaceuticals today announced it has been awarded “the Top 100 China Innovative Pharmaceutical Enterprises” at the 2020 Hangzhou China Healthcare Summit of Entrepreneurs, Scientists and Investors…
View Details >

Asieris Pharmaceuticals announced today that the first patient was enrolled in and administered the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira®)….
View Details >

Today Asieris Pharmaceuticals announced the completion of their Series D Round of financing. This round of funding was led by Qiming Venture Partners, and joined by YF Capital, CICC Transfer Fund, V-Capital, Hengxu Capital, Homsun…
View Details >

“This Phase III clinical trial for the first-line treatment of NMIBC, a key step to verify the advantages and characteristics of APL-1202, is another milestone of Asieris,” commented Dr. Kevin Pan, founder and CEO of Asieris…
View Details >

APL-1501, which is independently developed by the Prodrug Accurate Drug Delivery (PADD) platform of Asieris, is an oral sustained-release product based on….
View Details >

Asieris has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device…
View Details >


Bladder cancer and other genitourinary tumors, Tumor immunotherapy…

      More >

APL-1202, APL-1702, APL-1301, APL-1401, APL-1501

Using the world’s leading drug R&D concepts to establish a unique drug R&D system

      More >

Partner With Us

Contact us today for partnership opportunities